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Abstract
Introduction: In a considerable proportion of patients with childhood-onset growth hormone (GH) deficiency (GHD), a normalisation 
of GH secretion at the attainment of final height (FH) is observed. The aim of the present study was to assess the incidence of, and to 
find out the predictors of, persistent and transient GHD, available in the pre-treatment period, in patients with childhood-onset isolated, 
non-acquired GHD.
Material and methods: The analysis comprised 150 short children (117 boys), with childhood-onset isolated, non-acquired GHD who 
completed GH therapy and attained FH. Before treatment and at FH (in retesting), auxological parameters were measured, GH peak in 
stimulation tests and IGF-I concentration were assessed, and pituitary height (PHt) was measured before treatment. 
Results: The incidence of persistent GHD was 12.0%. The patients with persistent GHD had before treatment significantly lower GH and 
IGF-I secretion, as well as significantly better increase of height SDS (DHSDS) during GH therapy than those with transient GHD. A nega-
tive correlation was observed between DHSDS and IGF-I concentration, but not between DHSDS and GH peak. There was no significant 
difference in the incidence of pituitary hypoplasia between the patients with persistent and transient GHD.
Conclusions: The incidence of persistent GHD in patients with childhood-onset, isolated, non-acquired GHD is relatively low. Despite 
the fact that the predictors of persistent and transient GHD may be identified in childhood, a diagnosis of GHD should be verified in 
retesting after the attainment of FH in each case. (Endokrynol Pol 2014; 65 (5): 334–341)
Key words: short stature; growth hormone deficiency (GHD); growth hormone therapy; insulin-like growth factor-I; final height; persistent 
GHD; transient GHD
Streszczenie
Wstęp: U znacznej części pacjentów z rozpoznaną w dzieciństwie somatotropinową niedoczynnością przysadki (SNP) stwierdza się nor-
malizację wydzielania hormonu wzrostu (GH) po osiągnięciu wzrostu końcowego (FH). Celem pracy była ocena częstości i czynników 
prognostycznych trwałego i przemijającego niedoboru GH u dzieci z rozpoznaną w dzieciństwie izolowaną, nienabytą SNP. 
Materiał i metody: Analizą objęto 150 dzieci (117 chłopców) z niedoborem wzrostu, z rozpoznaną w dzieciństwie izolowaną, nienabytą 
SNP, którzy zakończyli terapię GH i uzyskali FH. Przed leczeniem i po osiągnięciu FH oceniono wybrane wskaźniki auksologiczne oraz 
wydzielanie GH i IGF-I; przed leczeniem zmierzono ponadto wysokość przysadki (PHt). 
Wyniki: Częstość trwałego niedoboru GH wynosiła 12,0%. Pacjenci z trwałym niedoborem GH mieli przed leczeniem znamiennie niższe 
wydzielanie GH i niższe stężenia IGF-I, a także uzyskali większy przyrost SDS wysokości ciała (DHSDS) podczas terapii GH niż pacjenci 
z przemijającym niedoborem GH. Stwierdzono ujemną korelację pomiędzy DHSDS i wydzielaniem IGF-I, przy braku korelacji między 
DHSDS a wydzielaniem GH. Częstość występowania hipoplazji przysadki u pacjentów z trwałym i przejściowym niedoborem GH nie 
różniła się znamiennie.
Wnioski: Częstość trwałego niedoboru GH u pacjentów z rozpoznaną w dzieciństwie izolowaną, nienabytą SNP jest względnie niska. 
Pomimo istnienia czynników warunkujących trwały niedobór GH w tej grupie pacjentów, możliwych do zidentyfikowania w momencie 
rozpoznania SNP w dzieciństwie, u wszystkich pacjentów z tej grupy rozpoznanie niedoboru GH wymaga weryfikacji podczas ponownej 
diagnostyki przeprowadzonej po uzyskaniu FH. (Endokrynol Pol 2014; 65 (5): 334–341)
Słowa kluczowe: niedobór wzrostu; somatotropinowa niedoczynność przysadki; leczenie hormonem wzrostu; insulinopodobny czynnik 
wzrostowy-I (IGF-I); wzrost końcowy; trwały niedobór GH; przemijający niedobór GH 
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Material and methods 
This retrospective analysis comprised 150 short children 
(117 boys, 33 girls), with childhood-onset isolated, 
non-acquired GHD who completed GH therapy and 
attained FH. Patients' age at GH therapy onset was 
12.5 ± 2.7 years (mean ± SD). The therapy with GH in 
a mean dose of 0.19 ± 0.06 mg (0.57 ± 0.06 IU)/kg/week 
was administered during 4.7 ± 2.2 years, up to the mo-
ment of fulfilling the criteria of its completion, i.e. when 
either bone epiphyses were closed or height velocity 
during treatment decreased below 2 cm/year. 
Short stature was defined as patient's height below 
the 3rd centile for age and sex. Reference data for Polish 
children [11] was used, assuming an exact value of –1.88 
for height SDS (HSDS) as an equivalent to 3rd centile. 
Both the patients and their parents were measured 
using a Harpenden stadiometer according to the rules 
of height measurement. The measurement of parents 
was performed in order to calculate patients’ target 
height (TH) and TH SDS. 
Before treatment, 86 patients were prepubertal, and 
the remaining 64 were pubertal — in II or III stage of 
puberty according to Tanner’s scale, and all the girls 
were premenstrual; before retesting, all the patients 
had completed puberty. 
Bone age (BA) of the patients was evaluated on the 
basis of the radiogram of the non-writing (in most cases 
— left) hand and wrist, with respect to the Greulich-
Pyle standards [12].
All the patients were diagnosed between 1997 and 
2009 in the Polish Mothers’ Memorial Hospital — Re-
search Institute and treated in the same centre up to FH.
The diagnosis of GHD in childhood was based on 
GH peak below 10 ng/mL in two stimulation tests — with 
clonidine (0.15 mg/m2, orally) and with either insulin 
(0.1 IU/kg, i.v.) or glucagon (30 μg/kg, i.m.). Severe GHD 
(sGHD) was diagnosed for GH peak below 5 ng/mL, 
and partial GHD (pGHD) for GH peak 5–10 ng/mL. 
In all patients, at least one month after completion 
of GH therapy, GH secretion was re-assessed in two 
stimulation tests — one with insulin and one with 
clonidine. Persistent GHD was diagnosed if GH peak 
in both tests was below 6 ng/mL, while transient GHD 
was diagnosed if GH peak at any time point of any test 
was greater than or equal to 6 ng/mL. Blood samples for 
GH estimation were collected every 30 min (from 0 to 
120 min) in the tests with insulin and with clonidine, 
and at 0, 90, 120, 150, and 180 min in the test with 
glucagon. The concentrations of GH were measured by 
a two-site chemiluminescent enzyme immunometric 
assay (hGH IMMULITE, DPC). 
Additionally, IGF-I serum concentrations were 
measured in all the patients at GH therapy onset and 
 Introduction
It is well known that in a considerable proportion of 
patients with childhood-onset growth hormone (GH) 
deficiency (GHD), a normalisation of GH secretion is 
observed after the attainment of adult height and the 
withdrawal of growth-promoting therapy. Moreover, it 
has been clearly established that the cut-off value for 
GH peak in stimulation tests may be lower in adult-
hood than in childhood. Namely, for young adults, it 
is sufficient to achieve a GH peak in insulin tolerance 
test (ITT) at a level of 6.0 ng/mL [1–3]. 
In recent classifications, GHD has been defined as 
a secondary insulin-like growth factor (IGF-I) deficiency 
[4, 5]. Nevertheless, in current recommendations, the 
statement that — in adults — normal IGF-I concentra-
tion does not exclude GHD has been strongly empha-
sised [1, 3, 6–9], as an overlap in IGF-I levels between 
patients with GHD and normal controls has been re-
ported [2]. On the other hand, it has been suggested in 
the same studies [2, 7, 9] that a very low IGF-I concentra-
tion might be diagnostic of GHD in the transition phase.
Numerous studies have shown that persistent 
GHD is highly probable in patients with multiple 
pituitary hormone deficiency, especially in cases of 
deficiency of at least three hormones, as well as in 
ones with isolated GHD caused by an identified mu-
tation related to the functioning of the somatotropic 
axis [1, 3, 8]. Such patients do not require further 
diagnostics at the attainment of final height (FH), 
while — in the remaining subjects — a re-evaluation 
of GH secretion (so-called ‘retesting’) seems neces-
sary [1]. However, among patients with isolated GHD 
diagnosed in childhood, the incidence of persistent 
GHD has been estimated as 40–75% [3], while in case 
of idiopathic GHD, a normalisation of GH secretion 
in the transition period has been reported in an even 
wider range of 20–88% [10]. 
Finally, very recently, Quigley et al. [8] have clearly 
stated that data on predictive factors of persistent GHD 
in patients with idiopathic GHD diagnosed in child-
hood is lacking. 
With respect to such data, it would appear worth-
while to search for the predictors of persistent GHD in 
patients with childhood-onset isolated, non-acquired 
GHD, particularly if any such predictors could be iden-
tified not only after completion of growth-promoting 
therapy, but also before the therapy onset.
The aim of the present study was to assess the 
incidence of, and to find out the factors predictive of, 
persistent and transient GHD available in the pre-treat-
ment period in patients with childhood-onset isolated, 
non-acquired GHD who completed GH therapy and 
attained FH.
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— again — together with the retesting of GH secretion. 
IGF-I concentrations were assessed by a solid-phase, 
enzyme-labelled chemiluminescent immunometric 
assays (IMMULITE, DPC). Next, for each patient, the 
value of IGF-I SDS for chronological age and sex was 
calculated according to the reference data provided 
by the manufacturer. The logarithmic transformation 
of measured values before making further calculations 
was performed, as suggested by Blum and Schweitzer 
[13]. The calculation of IGF-I SDS was necessary to make 
possible the comparisons of IGF-I secretion among 
different patients, as well as in the same patient in dif-
ferent time points.
In all patients, the following auxological parameters 
were assessed:
 — patient's height before treatment (H0SDS) and at the 
attainment of FH (FH SDS);
 — height SDS corrected by TH SDS at therapy onset 
(corrH0SDS) and at FH (corrFH SDS);
 — bone age (BA) delay with respect to chronological 
age (CA) at GH therapy onset, expressed as BA/CA 
ratio;
 — an increase of height SDS during the therapy  
(DHSDS = FH SDS – H0SDS).
In 139 out of 150 patients, magnetic resonance (MR) 
imaging (MRI) of the hypothalamic-pituitary region 
was performed before GH therapy, using a 1.5-Tesla 
MRI unit (Picker, model Edge), with sagittal and coronal 
slices, their thickness of 2–3 mm, depicted as midline 
images on T1-weighted, before and after gadolinium in-
jection. Pituitary height (PHt) was measured routinely 
as the greatest distance between the base and the top 
of the gland on the mid-sagittal T1-weighted image, in 
a plane perpendicular to the base of the sella turcica, 
after magnification through an overhead projector and 
using the scaling provided on the films (the accuracy 
of measurement: 0.1 mm). Moderate-to severe pituitary 
hypoplasia was diagnosed for PHt below or equal 
3 mm, as defined by Maghnie et al. [14]. Patients with 
decreased PHt, isolated or connected with pituitary 
stalk interruption syndrome (seven cases) and/or the 
ectopy of posterior pituitary (one case) and/or empty 
sella syndrome (four cases) were eligible for the study 
(all patients subjected to the study had isolated GHD 
and no other pituitary hormone deficiencies).
Next, the results of PHt measurements were com-
pared to the normal values for the given age, published 
by Argyropoulu et al. [15] and expressed as PHt SDS, 
with reference to CA and to height age (HA). The pitui-
tary gland was considered hypoplastic when PHt SDS 
was below -2.0 for CA and for HA. In short children, 
HA is below CA, so — in some cases — the pituitary 
gland, classified as hypoplastic with reference to nor-
mative data for CA, turned out to be normal for HA. 
In the remaining 11 subjects (three with persistent and 
eight with transient GHD), MR examination was also 
performed, but either with another unit or with thicker 
slices, showing no abnormalities in the hypothalamic-
pituitary region; nevertheless, these patients were 
excluded from the last part of the analysis. 
The exclusion criteria encompassed patients with:
 — any other detectable congenital abnormalities in the 
central nervous system;
 — acquired brain damage (including neurosurgery, 
brain injuries, history of inflammatory processes, 
history of cranial irradiation);
 — acquired GHD of any cause;
 — other pituitary hormone deficiencies and endocrine 
diseases;
 — any chronic diseases (diagnosed before or during 
GH therapy);
 — congenital defects of internal organs;
 — perinatal trauma;
 — dysmorphic features and diagnosed, or even sus-
pected, genetic syndromes (in girls, Turner syn-
drome was excluded by the karyotype assessment).
Non-acquired GHD was defined by the lack of an 
identifiable cause of decreased GH secretion, related 
to the perinatal and postnatal period (including the 
patient’s history, concomitant diseases and the result 
of MR examination).
Statistical analysis included non-parametric Mann-
Whitney’s U test for independent samples for the as-
sessment of differences among the groups in particular 
time points, and Wilcoxon’s test for dependent samples 
for comparison of the same parameter in the same 
group in different time points (before treatment and 
at FH). The analysis of correlations was performed by 
calculating Pearson’s correlation coefficients. The chi2 
Pearson’s test was used for the analysis of the incidences 
of pituitary hypoplasia in particular groups of patients. 
This study was approved by the local Ethics Com-
mittee of the Polish Mothers’ Memorial Hospital — 
Research Institute.
Results
The relationships between hormonal (GH and IGF-I 
secretion), auxological (indices of somatic growth, BA 
delay) and radiological (PHt) findings before GH ther-
apy onset and the incidence of persistent and transient 
GHD in retesting have been assessed. 
GH and IGF-I secretion before treatment  
and during retesting 
In the analysed group of 150 patients, there were 
30 children with an initial diagnosis of sGHD and 
120 with pGHD before the administration of GH therapy. 
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At the attainment of FH, persistent GHD, i.e. GH peak in 
two stimulation tests below 6 ng/mL, was observed in 
18 patients, comprising nine with previously diagnosed 
sGHD and nine with pGHD. Thus the total incidence of 
persistent GHD was 12.0%. Persistent GHD was more 
frequently observed in the patients with an initial diag-
nosis of sGHD (30.0%) than in those with pGHD (7.5%). 
Taking into account only the result of ITT, we would have 
diagnosed persistent GHD in 35 cases (23.3%). 
Significant differences between patients with final 
diagnoses of persistent GHD and transient GHD were 
observed in GH peak before treatment (4.9 ± 2.8 ng/mL 
vs. 7.3 ± 2.9 ng/mL, respectively, p < 0.05), as well as in 
IGF-I SDS (–2.13 ± 2.47 vs. –1.14 ± 1.58, respectively, 
p < 0.05), while the difference in IGF-I SDS after GH 
therapy withdrawal between the groups with per-
sistent and transient GHD did not reach the level of 
significance (–1.81 ± 2.02 vs. -0.65 ± 1.24, respectively, 
p = 0.07) (Figs. 1 and 2).
There was absolutely no correlation between GH 
peak and IGF-I SDS before treatment (r = 0.02, NS), 
while a correlation was found between IGF-I SDS 
before treatment and after completion of GH therapy 
(r = 0.27, p < 0.05). Moreover, no correlation was 
observed between GH peak before treatment and in 
retesting (r = 0.17, p < 0.05), and only a poor correla-
tion between GH peak in retesting and simultaneously 
assessed IGF-I SDS (r = 0.22, p < 0.05). 
Auxological assessment before treatment and at 
the attainment of FH
There was no significant difference in any of the ana-
lysed auxological indices before treatment (patients' age, 
H0SDS, corrH0SDS, BA/CA ratio) between the patients 
with persistent GHD and transient GHD. However, 
both the attained FH SDS and DHSDS were significantly 
better in patients with persistent GHD than in those 
with transient GHD (Table I).
Table I. Selected pre- and post-treatment auxological data of the patients with persistent and transient GHD 
Tabela I. Wybrane wskaźniki auksologiczne pacjentów z trwałym i przemijającym GHD ocenione przed leczeniem i po jego 
zakończeniu
Persistent GHD Transient GHD p
Age at therapy onset (years)  12.7  ±  3.4  12.5  ±  2.6 0.68
H0SDS  –3.16  ±  0.85  –3.04  ±  0.73 0.51
TH SDS  –0.86  ±  0.90  –1.26  ±  0.80 0.07
corrH0SDS  –2.01  ±  1.48  –1.78  ±  1.00 0.33
BA/CA  0.78  ±  0.15  0.83  ±  0.08 0.22
Age at FH (years)  17.0  ±  1.4  17.3  ±  1.1 0.61
FH SDS  –0.77  ±  0.88  –1.56  ±  0.86 0.001
corrFH SDS  –0.09  ±  1.10  –0.30  ±  0.88 0.28
DHSDS  2.39  ±  1.39  1.48  ±  0.87 0.003
a, b — significant differences (p < 0.05)
Figure 2. IGF-I SDS before GH therapy and during retesting in 
the patients with persistent and transient GHD
Rycina 2. Wartości IGF-I SDS przed rozpoczęciem terapii GH 
i podczas retestingu u pacjentów z trwałym i przemijającym GHD
Figure 1. GH peak in stimulation tests before GH therapy and 
in retesting in the patients with persistent and transient GHD, 
diagnosed at the attainment of FH
Rycina 1. Maksymalne wydzielanie GH w testach stymulacyjnych 
przed rozpoczęciem leczenia hormonem wzrostu i podczas 
ponownej oceny (retestingu)  po uzyskaniu FH u pacjentów 
z trwałym i przemijającym GHD
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Strong, negative correlations were observed be-
tween H0SDS and DHSDS (r = –0.50, p < 0.05), as well 
as between corrH0SDS and DHSDS (r = –0.55, p < 0.05).
There was no correlation between GH peak before 
treatment and DHSDS and (r = -0.14, NS), while a cor-
relation was observed between DHSDS and IGF-I SDS 
before treatment (r = -0.23, p < 0.05) (Figs. 3 and 4). 
Similarly, no correlation was found between GH peak 
in retesting and DHSDS (r = –0.10, NS), while there was 
a correlation between IGF-I SDS during retesting and 
DHSDS (r = –0.32, p < 0.05). 
MRI findings before treatment
Among the 139 patients in whom standardised MRI was 
performed, pituitary hypoplasia, defined as PHt equal 
to or below 3 mm, was found in 15 patients (10.8%), 
comprising eight children with sGHD and seven chil-
dren with pGHD. Among the patients with PHt below 
or equal to 3 mm, persistent GHD was diagnosed at FH 
in four of them, and transient GHD in 11. 
Thus, the incidence of such defined pituitary hypo-
plasia in the group of 15 patients with persistent GHD 
and assessed PHt was 26.7%, while in the group of 
124 ones with transient GHD and assessed PHt it was 
8.9% (the difference in the incidence of pituitary hypo-
plasia between the groups was insignificant). 
On the other hand, according to the normative 
data of Argyropoulu et al. [15], 65 had decreased 
PHt SDS for CA, while in the remaining 63 ones, 
PHt SDS was normal. Moreover, there was no dif-
ference in the mean PHt SDS between the patients 
with persistent and transient GHD (–1.63 ± 3.28 vs. 
–1.78 ± 2.06, NS). However, in three of the patients, 
the pituitary gland was significantly enlarged with 
no visible pituitary adenoma: in one patient with 
persistent GHD (in whom PHt SDS was 8.13) and in 
two patients with transient GHD (with PHt SDS 6.58 
and 3.38). Thus we decided to exclude them from 
further analysis. Taking into account the remain-
ing 136 cases, PHt SDS for CA was slightly lower in 
the patients with persistent GHD than in ones with 
transient GHD (–2.38 ± 1.75 vs. –1.92 ± 1.80, NS). Pi-
tuitary hypoplasia with respect to the normative data 
for CA was observed before treatment in 10 out of 
18 patients with persistent GHD (55.6%) and in 59 out 
of 120 patients with transient GHD (49.2%). 
Next, a similar analysis was performed for PHt as-
sessed with respect to patients' height (expressed as 
HA). Before treatment, PHt SDS for HA was lower in the 
patients with persistent GHD than in ones with tran-
sient GHD (–1.88 ± 1.91 vs. –1.21 ± 1.90), although still 
insignificantly. The incidence of pituitary hypoplasia for 
HA in patients with persistent GHD was 46.2%, while 
in those with transient GHD it was 30.2 % (the differ-
ence in the incidence of pituitary hypoplasia between 
these groups was insignificant). Moreover, there was 
no correlation between PHt SDS (both for CA and for 
HA) and GH peak at diagnosis in childhood (r = 0.18, 
NS and r = 0.20, p < 0.05, respectively), as well as no 
correlation between PHt SDS (both for CA and for 
HA) and GH peak in retesting (r = 0.11 and r = 0.13, 
respectively, NS), 
Thus, in the studied group of children with iso-
lated GHD and excluded organic abnormalities in the 
Figure 4. Correlation between IGF-I concentration before 
treatment and HSDS increase during GH therapy
Rycina 4. Korelacja pomiędzy wartością IGF-I SDS przed 
rozpoczęciem leczenia i poprawą wartości HSDS podczas terapii 
GH
Figure 3. Correlation between GH peak in stimulation tests before 
treatment and HSDS increase during GH therapy
Rycina 3. Korelacja pomiędzy maksymalnym wydzielaniem GH 
w testach stymulacyjnych przed rozpoczęciem leczenia i poprawą 
wartości HSDS podczas terapii GH
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hypothalamic-pituitary region, PHt was not a predictor 
of persistent and transient GHD. 
Discussion
A high incidence of persistent GHD has been reported 
in patients with structural abnormalities in the hypo-
thalamic-pituitary region [3, 8, 9], while GH secretion 
has been shown to normalise at the attainment of FH 
in patients with isolated GHD, even if the pituitary 
gland before treatment was small and/or ectopy of 
posterior pituitary lobe, and/or pituitary stalk inter-
ruption was found [9, 16]. The incidence of persistent 
GHD, observed in our study, was only 12%, relatively 
low with respect to other reports [3, 13]. This difference 
seems to be caused by a strict selection to the analysis 
only the patients with isolated GHD and the exclusion 
of all children with known causes of GHD except for 
those with anterior pituitary hypoplasia. Nevertheless, 
persistent GHD was confirmed more frequently in the 
patients with severe GHD than in those with partial 
GHD diagnosed in childhood. However, the incidence 
of persistent GHD in patients diagnosed in childhood 
as having sGHD, at 30%, is quite low. 
According to the current recommendations [1, 3, 
6, 17], in order to confirm GHD after the completion 
of growth-promoting therapy, it is sufficient to prove 
decreased GH peak in only one stimulation test. 
However, it has also been recently suggested that two 
stimulation tests should be used in order to diagnose 
isolated GHD in adults (due to a significant false-
positive error rate in GH response in a single test) [7]. 
In our study, on the basis of the result of ITT, we would 
have diagnosed persistent GHD with almost double 
the incidence than taking into account the results of 
two stimulation tests. Another proposal for retesting 
is to lower the cut-off value of GH peak in ITT to 
5 ng/mL [8, 18] or to 5.6 ng/mL [19]. In the whole studied 
group, only three patients (one with a previous diag-
nosis of sGHD and two with pGHD) had GH peak at 
FH between 5 ng/mL and 6 ng/mL. So, the incidence of 
persistent GHD, defined as GH peak in retesting in two 
stimulation tests below 5 ng/mL, was 10.0%. 
Thus, our results may be explained by performing 
two stimulation tests in each patient. That approach 
significantly reduces the number of patients diagnosed 
at FH as GH-deficient. The results of the present study 
indicate a high incidence of false positive results of ITT, 
if this was used as the only GH stimulation test dur-
ing retesting. Similar was the statement of Quigley et 
al. [8] who performed a single GH stimulation test to 
reassess the patients with multiple pituitary hormone 
deficiency, and two tests to confirm persistent isolated 
GHD. Moreover, our findings point at the possibility 
of using the test with clonidine in transition period, 
although that test has not been recommended in adults 
[6, 9, 17]. It seems worth mentioning that — in our study 
— almost half of the patients with decreased GH peak 
in ITT had a normal GH peak in the test with clonidine. 
The last issue may be the criteria of how children are 
qualified for GH therapy in different countries, as well 
as the differences between populations. Very recently, 
Biczysko-Mokosa et al. [20] have reported the incidence 
of persistent GHD in Polish children from Western Po-
merania as 18.3%, with the cut-off value for GH peak 
in ITT 6.0 ng/mL. In the quoted study, persistent GHD 
has been more frequently observed in the patients with 
sGHD than in those with pGHD. These results are quite 
similar to those obtained in our study. 
Next, it should be noted that a significant difference 
was found in IGF-I secretion before treatment between 
the patients with persistent and transient GHD, despite 
the lack of correlation between GH and IGF-I secretion 
before treatment. Moreover, the correlation between 
IGF-I SDS before treatment and in retesting was bet-
ter than the corresponding correlation between GH 
peaks in the same time points. This phenomenon may 
be partly related to the stability of IGF-I concentration 
and the variability of GH response to stimulation dur-
ing the repeated assessments, as has been previously 
reported in patients who were re-assessed in childhood 
[21, 22]. In the light of previous reports questioning the 
reliability of GH stimulation tests [21, 22] and pointing 
to the significance of secondary IGF-I deficiency for 
the diagnosis of GHD [4, 5], it seems that severe IGF-I 
deficiency before treatment should be considered as 
a no less reliable predictor of persistent GHD than the 
results of GH stimulation tests performed in childhood. 
Interestingly, despite the fact that the difference in IGF-I 
SDS during retesting between the patients with per-
sistent and transient GHD was insignificant, the mean 
value of IGF-I SDS before treatment was significantly 
lower in patients with persistent GHD than in those 
who normalised GH secretion. Our results remain in 
accordance with the data on the overlap between IGF-I 
secretion in the patients with persistent and transient 
GHD [2]. However, it has been proved that it is possible 
to establish a very low cut-off value of IGF-I SDS that 
reliably confirms persistent GHD, as well as another 
(higher) cut-off value that allows the exclusion of per-
sistent GHD [8]. Thus, the ‘grey zone’ — in which GH 
stimulation tests are necessary — is very wide. Unfor-
tunately, these threshold points may be appropriate 
only for the same method of IGF-I measurement and 
the same normative data.
In fact, we did not manage to find any auxological 
predictors of persistent and transient GHD, available 
at GH therapy onset. However, the effectiveness of 
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treatment was significantly better in the patients in 
whom GHD has proven to be persistent. Entirely 
consistent with our observations are the findings 
presented very recently by Krukowska-Andrzejczyk 
et al. [23] who have suggested relatively low effec-
tiveness of GH therapy in patients with an initial 
diagnosis of partial GHD and normal GH secretion 
in retesting.
The results of numerous studies indicate that 
organic abnormalities in the hypothalamic-pituitary 
region lead to more severe and persistent GHD and to 
the deficits of other pituitary hormones. In our present 
study, anterior pituitary hypoplasia, defined as PHt 
below or equal to 3 mm, has been found in 10.8% of 
the patients. In a very recent study of Maghnie et al. 
[14] on a relatively large cohort of over 15,000 patients, 
pituitary hypoplasia has been reported in a fairly similar 
proportion of the patients with isolated GHD. However, 
taking into account the normative data of Argyropoulu 
et al. [15], we should diagnose pituitary hypoplasia in 
approximately 50% of our patients, which seems to 
be clearly overestimated in the patients with isolated, 
non-acquired GHD. Thus, the choice of appropriate 
reference data seems to be of crucial importance to 
draw any valuable conclusions. 
It should be mentioned that somatotrophs comprise 
only about one third of anterior pituitary cells. Thus, 
pituitary volume depends on the amount of different 
cells. Even in a case of GHD caused by a decreased num-
ber of somatotrophs, it seems uncertain if this is related 
to a significant decrease of pituitary size. In 2007, Kalina 
et al. [24] reported that GH secretion was dependent 
on pituitary size only if there were coexisting structural 
defects in the hypothalamic-pituitary region, includ-
ing ectopy of the posterior pituitary and empty sella 
syndrome. In our present study, only a slightly higher 
incidence of decreased PHt was found in children with 
severe and persistent GHD than in those with partial 
and/or transient GHD.
Another important issue is the relationship between 
PHt and pituitary volume. It has been suggested that 
there is a good correlation between these two param-
eters [25]. Unfortunately, other findings have not dem-
onstrated such a correlation [26]. In fact, in our study, 
only PHt was assessed, assuming that this parameter 
should correspond to pituitary size. It is possible that 
the direct assessment of pituitary volume could lead to 
more significant results. On the other hand — as men-
tioned before — the poor reproducibility of the results 
of GH stimulation tests should be taken into account 
[21, 22]. Thus, there are several potential reasons why 
pituitary height may not correlate with its function, 
particularly with GH secretion, assessed on the ground 
of GH peak in stimulation tests.
Finally, studies on genetic defects leading to pitui-
tary hormone deficiencies have shown that impaired 
pituitary function may be related not only to pituitary 
hypoplasia (or other structural abnormalities) but also 
to pituitary enlargement, for instance in the patients 
with PROP1 mutations [27]. Unfortunately, in our study, 
a genetic assessment of the patients was not performed. 
However, we observed significant pituitary enlarge-
ment in three patients, while in others PHt was either 
normal or decreased. 
In conclusion, the results of our present study con-
firm the relatively low incidence of persistent GHD at 
the attainment of FH in patients with childhood-onset, 
isolated, non-acquired GHD. Despite the fact that there 
are predictors of persistent and transient GHD that 
may be identified before treatment, a diagnosis of GHD 
should be verified in retesting after the attainment of FH 
in each case before a decision is made as to the continu-
ation or discontinuation of GH therapy. 
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